軽度認知障害治療薬市場:パイプラインレビュー(2020年上半期)

◆英語タイトル:Mild Cognitive Impairment - Pipeline Review, H1 2020
◆商品コード:GDATA20MY0921
◆発行会社(リサーチ会社):Global Markets Direct
◆発行日:2020年3月31日
◆ページ数:125
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,000 ⇒換算¥210,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD4,000 ⇒換算¥420,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD6,000 ⇒換算¥630,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Global Markets Direct社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

Mild Cognitive Impairment – Pipeline Review, H1 2020
Summary

Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Mild Cognitive Impairment – Pipeline Review, H1 2020, provides an overview of the Mild Cognitive Impairment (Central Nervous System) pipeline landscape.

Mild cognitive impairment (MCI) is a condition involving problems with cognitive function (such as thinking, knowing and remembering). MCI is an intermediate stage between the expected cognitive decline of normal aging and the more serious decline of dementia. Symptoms include depression, irritability and aggression, anxiety and apathy. Risk factors include diabetes, high blood pressure, and depression, smoking and elevated cholesterol.

Report Highlights

Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Mild Cognitive Impairment – Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Mild Cognitive Impairment (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Mild Cognitive Impairment (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Mild Cognitive Impairment and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 8, 3, 1, 14 and 4 respectively. Similarly, the Universities portfolio in Phase II and Discovery stages comprises 1 and 1 molecules, respectively.

Mild Cognitive Impairment (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Mild Cognitive Impairment (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Mild Cognitive Impairment (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Mild Cognitive Impairment (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Mild Cognitive Impairment (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Mild Cognitive Impairment (Central Nervous System)

Reasons to Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Mild Cognitive Impairment (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Mild Cognitive Impairment (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

【レポートの目次】

Table of Contents
Introduction
Mild Cognitive Impairment – Overview
Mild Cognitive Impairment – Therapeutics Development
Mild Cognitive Impairment – Therapeutics Assessment
Mild Cognitive Impairment – Companies Involved in Therapeutics Development
Mild Cognitive Impairment – Drug Profiles
Mild Cognitive Impairment – Dormant Projects
Mild Cognitive Impairment – Discontinued Products
Mild Cognitive Impairment – Product Development Milestones
Appendix

List of Tables
Number of Products under Development for Mild Cognitive Impairment, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Products under Development by Universities/Institutes, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Target, H1 2020 (Contd..1), H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..1), H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Mild Cognitive Impairment - Pipeline by Addex Therapeutics Ltd, H1 2020
Mild Cognitive Impairment - Pipeline by AgeneBio Inc, H1 2020
Mild Cognitive Impairment - Pipeline by Avraham Pharmaceuticals Ltd, H1 2020
Mild Cognitive Impairment - Pipeline by Cerebrum Therapeutics Inc, H1 2020
Mild Cognitive Impairment - Pipeline by CereSpir Inc, H1 2020
Mild Cognitive Impairment - Pipeline by CuraSen Therapeutics Inc, H1 2020
Mild Cognitive Impairment - Pipeline by Eli Lilly and Co, H1 2020
Mild Cognitive Impairment - Pipeline by Fujifilm Toyama Chemical Co Ltd, H1 2020
Mild Cognitive Impairment - Pipeline by Grespo AB, H1 2020
Mild Cognitive Impairment - Pipeline by ImmunoChem Therapeutics LLC, H1 2020
Mild Cognitive Impairment - Pipeline by IntelGenx Corp, H1 2020
Mild Cognitive Impairment - Dormant Projects, H1 2020
Mild Cognitive Impairment - Dormant Projects, H1 2020 (Contd..1), H1 2020
Mild Cognitive Impairment - Discontinued Products, H1 2020

【掲載企業】

Addex Therapeutics Ltd
AgeneBio Inc
Avraham Pharmaceuticals Ltd
Cerebrum Therapeutics Inc
CereSpir Inc
CuraSen Therapeutics Inc
Eli Lilly and Co
Fujifilm Toyama Chemical Co Ltd
Grespo AB
ImmunoChem Therapeutics LLC
IntelGenx Corp
INVENT Pharmaceuticals Inc
Merck & Co Inc
NeurAegis Inc
NeuroActiva Inc
Neuron Biopharma SA
NLS Pharma Group
Octapharma AG
Partner Therapeutics Inc
Pfizer Inc
ProNeurogen Inc
Protekt Therapeutics Ltd
Sage Therapeutics Inc
SBI Pharmaceuticals Co Ltd
Therapix Biosciences Ltd

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[軽度認知障害治療薬市場:パイプラインレビュー(2020年上半期)]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆